Abstract:Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet production. First-line therapies include corticosteroids, intravenous immunoglobulin, and anti-D immunoglobulin. For patients who are refractory to these therapies, those who become corticosteroid dependent, or relapse following treatment with corticosteroid, options include splenectomy, rituximab, and thrombopoietin-receptor agonists, alongside a variety of additional immunosuppressive and experimental therapies. Despite recent advances in the management of ITP, many areas need further research. Although it is recognized that an assessment of patient-reported outcomes in ITP is valuable to understand and guide treatment, these measures are not routinely measured in the clinical setting. Consequently, although corticosteroids are first-line therapies for both children and adults, there are no data to suggest that corticosteroids improve health-related quality of life or other patient-related outcomes in either children or adults. In fact, long courses of corticosteroids, in either children or adults, may have a negative impact on a patient’s health-related quality of life, secondary to the impact on sleep disturbance, weight gain, and mental health. In adults, additional therapies may be needed to treat overt hemorrhage, but unfortunately the results are transient for the majority of patients. Therefore, there is a need to recognize the limitations of current existing therapies and evaluate new approaches, such as individualized treatment based on the probability of response and the size of effect on the patient’s most bothersome symptoms and risk of adverse effects or complications. Finally, a validated screening tool that identifies clinically significant patient-reported outcomes in routine clinical practice would help both patients and physicians to effectively follow a patient’s health beyond simply treating the laboratory findings and physical symptoms of ITP. The goal of this narrative review is to discuss management of newly diagnosed and refractory patients with ITP, with a focus on the limitations of current therapies from the patient’s perspective.

ITP in the 21st Century

ITP: a historical perspective

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management

Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters

Current Management of Primary Immune Thrombocytopenia

Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease

Immune thrombocytopenia (ITP): historical perspectives, pathophysiology, and treatment advances

Investigational drugs for immune thrombocytopenia

Emerging Drugs for Idiopathic Thrombocytopenic Purpura in Adults

Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management

A Review of Pathogenesis and Treatment Options

Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions

[Recent progress in immune thrombocytopenia pathophysiology and treatment]

Immune thrombocytopenic purpura

Immune Thrombocytopenia Nomenclature, Consensus Reports, and Guidelines: What Are the Consequences for Daily Practice and Clinical Research?

Contemporary management of primary immune thrombocytopenia in adults

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

Novel therapeutics and future directions for refractory immune thrombocytopenia

Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management

A Bibliometric Analysis of Primary Immune Thrombocytopenia from 2011 to 2021

Identifying and Treating Refractory ITP: Difficulty in Diagnosis and Role of Combination Treatment